HHS Issues Interim Enforcement Discretion Policy for Compounding of Six Peptides

The U.S. Department of Health and Human Services (HHS) has announced an interim enforcement discretion policy for state-licensed pharmacies, federal facilities, and licensed physicians compounding drug products using six specific peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. This policy allows continued access under specified conditions while the official 503A Bulks List is finalized through rulemaking.